Shareholders

 

Kunming Pharmaceutical Corp.

Chinese Partner: KPC

Founded in 1951, KPC (Shanghai Stock Exchange: 600422) is a national key high-tech enterprise and one of the top 50 enterprises of China’s pharmaceutical industry. With its rich professional experience in pharmaceuticals, it is an enterprise that integrates research & development, production, sales, wholesale sales and the international marketing of drugs. It has developed its own business structure based on natural botanical drugs that covers the fields of traditional Chinese medicine, pharmaceutical chemicals and medicine circulation. Through making use of the rich botanical resources of Yunnan, KPC has walked on a road of internationalization and the industrialization of high and new technologies. It is a unique enterprise than engages in the research & development and production of natural TCM, ethnic and other drugs and has developed more than 40 new and advanced natural drug products both at home and abroad, including an artemether series, a pseudo-ginseng series, and a gastrodin series.

 

TEVA Pharmaceutical Industries Co., Ltd.

Foreign Partner: TEVA

As the biggest generics pharmaceutical company in the world, TEVA is engaged in the research & development as well as the production and promotion of generic drugs, patent brand drugs and active ingredients. It possesses more than 20 wholly-owned subsidiaries across the globe and ranks 15th among the pharmaceutical enterprises of the world. The global sales revenue of TEVA was USD 17.2 billion in 2012. KBN is one of the most successful projects in which TEVA has invested in China, so TEVA attaches great importance to KBN’s development prospects and investment value and now is actively preparing to expand its investment with KBN as a business platform for that expansion.